Pharmaceutical traffic between Europe and Brazil is climbing at LATAM Cargo, and the carrier points to GLP-1 medications — the drug class behind Ozempic, Wegovy and related therapies — as the decisive driver of the surge.

The growth marks a shift in the composition of the Europe–South America trade lane. Where pharma volumes on the corridor were once dominated by vaccines, temperature-sensitive biologics and traditional medicines, incretin-based treatments produced at European manufacturing sites are now generating sustained, high-yield demand for cold-chain lift into Brazil.

GLP-1 shipments carry specific handling requirements. The products move under tight temperature control, typically within the 2–8°C band or as validated cold-chain kits, and each consignment demands documented temperature integrity from European production and packing sites through to Brazilian consignees. That profile favors carriers able to guarantee active or passive temperature-controlled containers, validated cool-chain procedures and short tarmac exposure — capabilities LATAM Cargo has built out across its network in recent years.

The volume trend matters commercially. Pharma freight historically commands premium rates compared with general cargo, because shippers pay for reliability and temperature assurance rather than pure capacity. Rising GLP-1 output from European producers — a manufacturing base that has struggled at times to keep pace with global demand for the drugs — creates recurring export flows toward Latin America's largest pharmaceutical market. Brazil, with a population above 210 million and expanding insurance coverage for metabolic and diabetes therapies, anchors that demand.

For LATAM Cargo, the pharma surge diversifies revenue on a lane where southbound holds have traditionally carried machinery, chemicals and e-commerce goods at softer yields. Strengthening cold-chain volumes from Europe helps balance directional flows and improves the economics of the carrier's widebody operations linking the two regions.

The competitive context is tightening. Carriers across the transatlantic and Europe–South America corridors have invested in CEIV Pharma certification and equivalent cool-chain programs to capture pharma share, and forwarders increasingly allocate GLP-1 volumes to certified lift only. LATAM Cargo's reported growth suggests its cool-chain credentials are converting manufacturing growth in Europe into booked tonnage on the Brazilian routes.

Industry analysts view pharmaceuticals as one of the most defensible air cargo segments, since demand tracks drug production schedules rather than trade cycles. The Europe–Brazil pharma trajectory reported by LATAM Cargo aligns with that pattern: as GLP-1 production scales and Brazilian uptake of the therapies widens, the lane's cold-chain volumes are positioned to keep rising through the coming quarters.